% | $
Quotes you view appear here for quick access.

PCS Message Board

bocamp1 303 posts  |  Last Activity: 30 minutes ago Member since: Oct 13, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Nice run since breakout. A little news on trial, which could come at anytime now, and 1++++

  • Reply to

    Don't understand this Board

    by joelsilverman212 Mar 28, 2016 2:58 PM
    bocamp1 bocamp1 Mar 28, 2016 3:55 PM Flag

    OK, joel.
    But, i dont think i would come here as a newbie and call someone else stupid when you are the one using comments made on a yahoo investment board as even a small part of your investment decision. That is both nuts and naive.

    Its getting closer to big time results. RGRX getting more attention on twitter and some blogs. So, the influx of silly posters should be expected and likely will continue to grow.

  • Reply to

    Don't understand this Board

    by joelsilverman212 Mar 28, 2016 2:58 PM
    bocamp1 bocamp1 Mar 28, 2016 3:11 PM Flag

    Let me get this straight, you only made a "modest" purchase because you did not like the tone of the yahoo message board ? Come on. Thats a little hard to believe.
    You take that tone by a few disgruntled, malcontents, over your analysts comments.?

    Stock is priced so attractively because of some past trial failures. Upcoming 2 trial results have nothing to do with those. Trial being run by the best..ORA, and fully funded by Koreans, a very serious partner. Go check the valuation (almost solely based on rgrx's TB4) of GTREE.
    Many have maintained great chance of trial success based on prior dry eye, severe dry eye and NK trials. I suggest you ignore some and concentrate on the many positive comments here........if you insist on giving comments here such a large part of your investment decision making.....good luck

  • Reply to

    Hey Bocamp,,,,

    by donker3 Mar 28, 2016 8:58 AM
    bocamp1 bocamp1 Mar 28, 2016 9:05 AM Flag

    Donk, you are seriously unbalanced. Get some help.

  • Reply to

    Quality Posts

    by bernie.goldburg Mar 27, 2016 8:06 PM
    bocamp1 bocamp1 Mar 28, 2016 8:28 AM Flag

    "You appear to have self esteem issues and for some reason believe that putting statements and silly insults in all caps somehow increases the validity of your prose"
    You think?

    Carry on donk. Stock will be a buck and a 1/2 soon and you will still be posting drivel about a JV agreement you dont understand.

  • How many posts is that Donk? You must have the real family life on this Easter Weekend. Most are enjoying that family, you are hysterically posting more lies and attacking those of differing views. Me thinks you protest too loudly. As far as patent #, do your own DD. You are the highly paid, message board attorney. I know we have plenty of protection on the IP to see stock run much farther. And have done very nicely knowing that. But, you seem to know more than the market; no patents and a 70 mil market cap on it's way to 100 mil+.
    In all my years of biotech investing I have never seen a short like Donk try so hard to confuse investors in front of a binary trial result by focusing on a patent extension. The smart ones will attack the drug and trial itself(donk knows nothing here so he can not). Others might go after the present patent as being invalid; not the case here.
    So once again superfluous Donk, focus on trial. That means; look at earlier results. Did we hit all enpoints on the 28th day, but missed on the 29th. And might 4 drops improve that outcome and work around the 1/2 life? Did we hit total corneal staining on a previous trial? Is the FDA more accomodative now in the dry eye indication. What did Shire's purchase of it dry eye drug cost them after P3.
    I could go on but, you either are a convicted long waiting for a postive result, or a Donk. Now, lets here about that patent again.
    carry on donk

  • bocamp1 bocamp1 Mar 26, 2016 6:03 PM Flag

    Patent coverage is revelent, but you're saying that rgrx has no patent coverage(your words) is a lie.
    And in your elite, know it all mindset, you loss site of the scorecard here. And in a stock, its the stock price.
    And your worthless, see which way the wind is blowing, hold rating is a loser. Strong buys by me below a dime and strong rec to buy in that long gone consolidation phase, makes my comments a little more credible than your acedemic diatribes.
    And the math of the breakouts above the 200dma can not be denied. Two previous breakouts i pointed out led to a gain of exactly 260%. This latest breakout will take us to 1.5.

    Carry on donk.........
    And, JJ has final say in any sale of the JV. Get it, Donk?

  • The donk's ad nausuam posts about the patents just misses the mark...for now. The bottom line is that a patent extension(and that is what donk is talking about) is always good and always has value, but it is not important in terms of short term value here. The upcoming trial results(NK and Dry eye) are all that matter. That is the meat, and donk is talking gravey. (almost as good a cliche as your "bird in hand.") We have patent protection for 5 or so years. Will not getting this extension mean positive trial results wont add big time to price of rgrx's stock? Of course not. Positive trial results will push stock well above a buck.

    Dont never talks what is really important here because he knows little about the trials and their chances for success.
    Focus on Trial, ignore donk.

  • Reply to

    RGRX; Bullish Breakout with a 2.1 Target/March 24th

    by bocamp1 Mar 25, 2016 11:32 AM
    bocamp1 bocamp1 Mar 25, 2016 11:45 AM Flag

    Regarding developments on ReGreenTree joint venture which is between RGRX and G-treeBNT. G-treeBNT is a biotech venture in South Korea. The two companies are engaging in the development of its RGN-259 drug. G-treeBNT holds a significant, majority stake in RGRX and is funding and conducting the clinical trials and product development which is huge support and financial lift for the company. The joint venture has launched a new website to provide updates to investors. In addition, the joint venture is in the process of not one but two phase 3 clinical trials in the USA.
    RGRX incorporated on May 13, 1982, is a biopharmaceutical company. Its strategy is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tß4) for tissue and organ protection, repair and regeneration. It has formulated Tß4 into three product candidates in clinical development, which include RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration and RGN-137, a topical gel for dermal wounds and reduction of scar tissue.

  • Reply to

    RGRX; Bullish Breakout with a 2.1 Target/March 24th

    by bocamp1 Mar 25, 2016 11:32 AM
    bocamp1 bocamp1 Mar 25, 2016 11:35 AM Flag

    Technically speaking, the stock will likely peak out around the $0.83 level (22% gain from current levels) before it buds up against resistance. This will likely be a good point to take profits or at least lock in some gains. The stock will hopefully take a healthy amount of time to consolidate before breaking out on a bullish catalyst or development

    RGRX has been making advancements with its Joint Venture for its severe dry eye trial. It announced that its phase 2 trial had met its key objectives and data showed the drug demonstrated statistically significant improvement in corneal damage and eye discomfort. Impressively, improvements were seen within 28 days after the completion of treatment. The trial of phase 2/3 sponsored by a different LLC is not targeting severe dry eye like this drug treatment.

  • From MicroCap Spotlight

    RegeneRx Biopharmaceuticals Inc (OTCMKTS:RGRX) surges on milestones and recent developments of buy recommendation, joint venture, and enrollment for dry eyes. The stock price has been consolidating over the last year, and broke out of its base on high volume and skyrocketing share price sending shares over 50% from its base. The stock has been exceeding its daily average volume for several consecutive days now. RGRX appears to be set for more gains and could eventually reach a price target of $2.10+. This mean the stock is poised to almost triple from current levels.
    RGRX is ready for a breakout year after being stuck in consolidation mode for almost a year. In recent developments, the company announced that its TB4 drug had shown to improve and promote regeneration and repair of damaged central nervous system cells. This has a huge market with several million people diagnosed with dry eyes. There are several future catalysts that can push this stock forward. MicroCap Spot has featured this company in a prior post and the stock continues to post significant gains. Volume has seen a large expansion but has not reach the 1 million share trading volume club

  • Longs should have a great 3 day weekend. Stock closes at a 6 year high.
    Expect more negative nonsense as the stock continues to climb into trial results.

    Sentiment: Strong Buy

  • bocamp1 bocamp1 Mar 24, 2016 12:54 PM Flag

    The stupidity on this board reigns supreme. One guy thinks nite and cdel are colluding to manipulate stock lower. He feels his point is right on after it closed down a penny. Another says it must be true because cdel and nite are paying shills to do the damaging work of giving posts thumbs down....oh the humanity!
    And another, the resident yahoo message board legal expert, says rgrx has no IP protection as it only has 7 US patents. Of course, dry eye only needs one, but that really doesnt matter here
    And finally, these dolts think that everything said on this yahoo board must influence stock price.

    Keep an eye on trial results .....................Its is the ONLY thing that matters

  • bocamp1 by bocamp1 Mar 23, 2016 4:09 PM Flag

    If this was a big board stock, the technicians would be all over this thing. RGRX has broken out of a 9 month consolidation, breaking the 60 cent yearly high in the process on relatively big volume. Stock then pulls back to 55 cents to fill the gap and is now moving higher on good volume. Today, with the IBB getting slammed, the stock closes near the high of the day at .675(importantly above that 60 cent recent yearly high). This is up about 14%. And, throw in the fact that today was a bullish outside day, and you have one nice looking chart.

    If technicals mean anything, trial news very soon and very postive...................................

  • Reply to


    by sdhoolteach2000 Mar 22, 2016 12:14 PM
    bocamp1 bocamp1 Mar 22, 2016 4:26 PM Flag

    The only thing that repeated itself today was your continued moronic posts. Intelligent Investors who come to this board and read your nonsense must really get a laugh. Do you even have a clue as to what the function of nite and cdel is. They are mostly executing retail orders. There is no collusion between the 2.
    Today, a little buying and selling after gap at .55 filled.............all good
    But, you have seen it all stop being an idiot.

  • bocamp1 bocamp1 Mar 20, 2016 4:18 PM Flag

    In the past, this outsized volume would have eventually led to at least a short term spike in share price. But, so far nothing and huge seller continues to add to supply.
    This new company(IT netwolves & vaso) could really be the real deal. But, who would know? There is zero talk with the shareholder base. Or, it could just be another scam like the "accretive" China acquistions.
    This Q earnings report should be very telling. It would be to the company's advantage to let Castle handle most of the call. The first question might be what happened to those updates he promised on the last call?

  • Filing today. More incentive for managment
    Bove 100k
    McNay 100k
    JJ 200k
    Goldstien 200k

    All at 64 cents. Very fair, could have been done at that .45 last week. Very good sign

  • Reply to

    Tick trades today. 86k sells

    by snogreen Mar 18, 2016 4:31 PM
    bocamp1 bocamp1 Mar 18, 2016 4:35 PM Flag

    Look, you dumb #$%$. The trades explained to me, and i explained to you were on the downtick. Man, you are as thick as a brick.
    Focus on trial. Everything else is meaningless.

  • Reply to

    Dr P, Yes I followed up this morning

    by thebasiles777 Mar 18, 2016 10:14 AM
    bocamp1 bocamp1 Mar 18, 2016 12:25 PM Flag

    Look sno, i am just telling you what the finra rep told me. And i explained that i was looking at a BB stock. Of course, you know better. She gave me the example for a BB stock. So, i dont care to argue with you and your "intellect."
    There is no huge naked short here. But, believe whatever you want. I just wanted to clarify for the benefit of the board.

  • Reply to

    Dr P, Yes I followed up this morning

    by thebasiles777 Mar 18, 2016 10:14 AM
    bocamp1 bocamp1 Mar 18, 2016 11:39 AM Flag

    You are right bull. Most of this short talk is just nonsense. The finra short daily totals are a waste of time and not accurate in terms of real short interest.
    For example; if client wants to sell shares through nite, nite goes to another mm and looks for best bid. Nite then sells stock to MM. This is listed as a short. But, nite then goes and buys shares from the original client and is obviously flat. This is convoluted and makes no sense, but this is how they calculate that short number. It appears and inflates short finra stats but has no useful purpose in terms of real short activity.
    This is not my opinion, it is a real example given to me by Finra. In their effort to not double count volume, they do some things even they really cant explain. Even stock nite had on offer could be counted in the same way as above example.
    Best to keep focused on trials.

11.84-0.1100(-0.92%)Apr 30 3:59 PMEDT